 |
Source | Chin J Integr Med (2015). Figure 5. CYC116 |
| Method | Flow Cytometry Detection of Apoptosis | |
| Cell Lines | RPMI8226 Cell | |
| Concentrations | 0.5 mg/L | |
| Incubation Time | 24 h | |
| Results | For treatment with matrine or CYC116 alone, early apoptosis rates were 1.91% and 2.38%, respectively. However, the early apoptosis rate following combined drug treatment was 9.25%, indicating a synergistic effect of matrine and CYC116 on the induction of apoptosis in MM cells. |
| Cell Experiment | |
|---|---|
| Cell lines | HeLa, MCF7, MV4-11 and A2780 cells line |
| Preparation method | Cell Viability Assay. Inhibition of cell growth was measured by a standard MTT (thiazolyl blue; 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay using a panel of tumor cell lines.Briefly: cells were seeded (2,500–5,000 cells/well) in 96-well plates and allowed to attach for ~ 24 h. Cells were incubated with test compounds for 96 h in DMEM medium containing 10% fetal bovine serum. Cells were treated with a range of compound concentrations in triplicate to generate dose-response curves. The compound concentration required to inhibit 50% of cell growth (IC50) was determined using nonlinear regression analysis. |
| Concentrations | 0~10 μ M |
| Incubation time | 96 h |
| Animal Experiment | |
|---|---|
| Animal models | Murine P388/D1 Leukemia Model (1) / Murine NCI-H460 non-small cell lung cancer xenograft model (2) |
| Formulation | DMSO/ddH20 |
| Dosages | 45 or 67mg/kg twice daily on days 1-3 and 7-9(1) / 75 and 100mg/kg once daily starting on day 1 and for 5 days(2) |
| Administration | oral gavage |
| Molecular Weight | 368.46 |
| Formula | C18H20N6OS |
| CAS Number | 693228-63-6 |
| Solubility (25°C) | DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related Aurora Kinase Products |
|---|
| Aurora Kinases-IN-4
Aurora Kinases-IN-4 is a covalent and ATP competitive aurora kinase A inhibitor (IC50: 1.7 nM). |
| Derrone
Derrone, a prenylated isoflavones, is an Aurora kinase inhibitor, with IC50 values of 6 and 22.3 μM against Aurora B and Aurora A, respectively. Derrone shows anti-tumor activity. |
| CD532 hydrochloride
CD532 hydrochloride is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 hydrochloride has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 hydrochloride also can directly interact with AURKA and induces a global conformational shift. CD532 hydrochloride can be used for the research of cancer. |
| Aurora kinase inhibitor-2
Aurora kinase inhibitor-2 is a selective and ATP-competitive Aurora kinase inhibitor with IC50s of 310 nM and 240 nM for Aurora A and Aurora B, respectively. |
| AAPK-25
AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone H3Ser10 phosphorylation and followed by a surge in apoptosis. AAPK-25 targets Aurora-A, -B, and -C with Kd values ranging from 23-289 nM, as well as PLK-1, -2, and -3 with Kd values ranging from 55-456 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
